Rifaximin in Patients With Gastroesophageal Variceal Bleeding

Summary

The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

Timeline

Start

2016-11-25

Primary completion

2017-12-22

Completion

2018-02-28

Outcome

Met primary endpoint

paper the total liver-related score decreased significantly upon rifaximin therapy (-0.35 ± 0.14 vs 0.05 ± 0.14, p = 0.0465) PMID 39443081 ↗

Publications

• Huang XQ, Ai YJ, Li F, Ye ST, Wang JH, Zhang R, Zhang W, Zhu YL, Chen SY. Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial. J Dig Dis. 2024 Aug;25(8):504-516. doi: 10.1111/1751-2980.13314.
• Zacharias HD, Kamel F, Tan J, Kimer N, Gluud LL, Morgan MY. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD011585. doi: 10.1002/14651858.CD011585.pub2.

Drugs

Indications